SG11201806829TA - 6,7-dihydro-5h-benzo[7]annulene derivatives as estrogen receptor modulators - Google Patents

6,7-dihydro-5h-benzo[7]annulene derivatives as estrogen receptor modulators

Info

Publication number
SG11201806829TA
SG11201806829TA SG11201806829TA SG11201806829TA SG11201806829TA SG 11201806829T A SG11201806829T A SG 11201806829TA SG 11201806829T A SG11201806829T A SG 11201806829TA SG 11201806829T A SG11201806829T A SG 11201806829TA SG 11201806829T A SG11201806829T A SG 11201806829TA
Authority
SG
Singapore
Prior art keywords
sanofi
boetie
paris
patent department
international
Prior art date
Application number
SG11201806829TA
Inventor
Monsif Bouaboula
Maurice Brollo
Victor Certal
Youssef El-Ahmad
Bruno Filoche-Rommé
Frank Halley
Gary Mccort
Laurent Schio
Michel Tabart
Corinne Terrier
Fabienne Thompson
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of SG11201806829TA publication Critical patent/SG11201806829TA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/027—Organoboranes and organoborohydrides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/572—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrrole Compounds (AREA)
  • Steroid Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2017/140669 Al 24 August 2017 (24.08.2017) WIPO I PCT 1111111111111101110101011111010111110 0101111111011111111111110111111111110111111 (51) International Patent Classification: C07D 403/12 (2006.01) C07D 471/04 (2006.01) C07D 401/12 (2006.01) C07D 207/12 (2006.01) C07D 405/12 (2006.01) A61K 31/40 (2006.01) C07D 413/12 (2006.01) A61K 31/4025 (2006.01) C07D 417/12 (2006.01) A61P 35/00 (2006.01) (21) International Application Number: (22) International Filing Date: PCT/EP2017/053282 14 February 2017 (14.02.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 16305174.1 15 February 2016 (15.02.2016) EP (71) Applicant: SANOFI [FR/FR]; 54 me La Boetie, 75008 Paris (FR). (72) Inventors: BOUABOULA, Monsif; c/o Sanofi, Patent Department, 55 Corporate Drive, Mail code: 55A-505A, Bridgewater, New Jersey NJ 8807 (US). BROLLO, Maurice; c/o Sanofi, Patent Department, 54 me La Boetie, 75008 Paris (FR). CERTAL, Victor; c/o Sanofi, Patent Department, 54 rue La Boetie, 75008 Paris (FR). EL- AHMAD, Youssef; c/o Sanofi, Patent Department, 54 me La Boetie, 75008 Paris (FR). FILOCHE-ROMME, Bruno; c/o Sanofi, Patent Department, 54 me La Boetie, 75008 Paris (FR). HALLEY, Frank; c/o Sanofi, Patent Department, 54 me La Boetie, 75008 Paris (FR). MC- CORT, Gary; c/o Sanofi, Patent Department, 54 me La Boetie, 75008 Paris (FR). SCHIO, Laurent; c/o Sanofi, Patent Department, 54 me La Boetie, 75008 Paris (FR). TABART, Michel; c/o Sanofi, Patent Department, 54 me La Boetie, 75008 Paris (FR). TERRIER, Corinne; c/o Sanofi, Patent Department, 54 me La Boetie, 75008 Paris (FR). THOMPSON, Fabienne; c/o Sanofi, Patent Depart- ment, 54 me La Boetie, 75008 Paris (FR). (74) Agent: ROMANOWSKI, Caroline; c/o Sanofi, Patent Department, 54 me La Boetie, 75008 Paris (FR). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, [Continued on next page] (54) Title: 6,7-DIHYDRO-5H-BENZO[7]ANNULENE DERIVATIVES AS ESTROGEN RECEPTOR MODULATORS W O 20 17 / 140669 Al R5 R3 (I) (57) : The present invention relates to compounds of formula (I): wherein R1 and R2 represent hydrogen or deu- terium atoms; R3 represents a hydrogen atom or a -COOH, a -OH or a -0P0(OH)2 group; R4 represents a hydrogen atom or a fluorine atom; R5 represents a hydrogen atom or a -OH group; wherein at least one of R3 or R5 is different from a hydrogen atom; when R3 represents a -COOH, -OH or -0P0(OH)2 group, then R5 represents a hydrogen atom; when R5 represents a -OH group, then R3 and R4 represent hydrogen atoms; and R6 is selected from an optionally substi- tuted phenyl, heteroaryl, cycloalkyl or heterocycloalkyl group. The invention also relates to the preparation and to the therapeutic uses of the compounds of formula (I) as inhibitors and degraders of estrogen receptors, useful especially in the treatment of cancer. R4 WO 2017/140669 Al MIDEDIMOMOIDEIRMEMOMMHOIEMIEHOMEMOIS TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, Declarations under Rule 4.17: VN, ZA, ZM, ZW. of inventorship (Rule 4.17(iv)) (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: with international search report (Art. 21(3)) before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
SG11201806829TA 2016-02-15 2017-02-14 6,7-dihydro-5h-benzo[7]annulene derivatives as estrogen receptor modulators SG11201806829TA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16305174 2016-02-15
PCT/EP2017/053282 WO2017140669A1 (en) 2016-02-15 2017-02-14 6,7-dihydro-5h-benzo[7]annulene derivatives as estrogen receptor modulators

Publications (1)

Publication Number Publication Date
SG11201806829TA true SG11201806829TA (en) 2018-09-27

Family

ID=55398242

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201806829TA SG11201806829TA (en) 2016-02-15 2017-02-14 6,7-dihydro-5h-benzo[7]annulene derivatives as estrogen receptor modulators
SG10202106024XA SG10202106024XA (en) 2016-02-15 2017-02-14 6,7-dihydro-5h-benzo[7]annulene derivatives as estrogen receptor modulators

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10202106024XA SG10202106024XA (en) 2016-02-15 2017-02-14 6,7-dihydro-5h-benzo[7]annulene derivatives as estrogen receptor modulators

Country Status (37)

Country Link
US (6) US9714221B1 (en)
EP (2) EP3416962B1 (en)
JP (4) JP6425852B1 (en)
KR (2) KR20220098057A (en)
CN (2) CN112979524A (en)
AR (1) AR107616A1 (en)
AU (2) AU2017221083B2 (en)
BR (1) BR112018016490A2 (en)
CA (1) CA3014424A1 (en)
CL (1) CL2018002290A1 (en)
CO (1) CO2018009534A2 (en)
CR (1) CR20180442A (en)
CY (1) CY1125165T1 (en)
DK (2) DK3416962T3 (en)
DO (1) DOP2018000184A (en)
EA (2) EA034994B1 (en)
EC (1) ECSP18069466A (en)
ES (2) ES2906208T3 (en)
HR (1) HRP20211043T1 (en)
HU (2) HUE057892T2 (en)
IL (2) IL261099B (en)
LT (1) LT3416962T (en)
MA (2) MA46479A (en)
MX (2) MX2020011469A (en)
MY (1) MY196486A (en)
PE (1) PE20181893A1 (en)
PH (1) PH12018501679A1 (en)
PL (1) PL3416962T3 (en)
PT (1) PT3416962T (en)
RS (1) RS62132B1 (en)
SG (2) SG11201806829TA (en)
SI (1) SI3416962T1 (en)
TN (1) TN2018000285A1 (en)
TW (3) TWI779620B (en)
UY (1) UY37124A (en)
WO (1) WO2017140669A1 (en)
ZA (1) ZA201805137B (en)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3416962T3 (en) 2016-02-15 2021-11-22 Sanofi 6,7-dihydro-5h-benzo[7]annulene derivatives as estrogen receptor modulators
SG11201903908PA (en) * 2016-11-17 2019-05-30 Sanofi Sa Novel substituted n-(3-fluoropropyl)-pyrrolidine compounds, processes for their preparation and therapeutic uses thereof
WO2018148576A1 (en) 2017-02-10 2018-08-16 G1 Therapeutics, Inc. Benzothiophene estrogen receptor modulators
EP3434272A1 (en) * 2017-07-25 2019-01-30 Sanofi Combination comprising palbociclib and 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylic acid
US11759450B2 (en) 2018-02-06 2023-09-19 The Board Of Trustees Of The University Of Illinois Substituted benzothiophene analogs as selective estrogen receptor degraders
AU2019321588A1 (en) 2018-08-17 2021-03-04 Genentech, Inc. Diagnostic and therapeutic methods for the treatment of breast cancer
ES2923412T3 (en) * 2018-09-07 2022-09-27 Sanofi Sa 6-(2,4-dichlorophenyl)-5-[4-[(3S)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7H-benzo[7] salts Methyl annulene-2-carboxylate and preparation process thereof
EP3699167A1 (en) 2019-02-22 2020-08-26 Sanofi Process for preparing methyl 1-benzosuberone-7-carboxylate
SG11202111979SA (en) 2019-05-09 2021-11-29 Sanofi Sa 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylic acid for use in metastatic or advanced breast cancer patients
KR102058384B1 (en) * 2019-09-06 2019-12-24 강원대학교산학협력단 2h-benzo[7]annulene compounds and its preparation method
WO2021063967A1 (en) 2019-10-01 2021-04-08 Sanofi Novel substituted 6,7-dihydro-5h-benzo[7]annulene compounds, processes for their preparation and therapeutic uses thereof
CA3160897A1 (en) 2019-12-09 2021-06-17 Sanofi Crystalline form of a 7h-benzo[7]annulene-2-carboxylic acid derivative
TW202146007A (en) * 2020-02-27 2021-12-16 法商賽諾菲公司 Combination comprising alpelisib and 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylic acid
CN113896669A (en) * 2020-06-22 2022-01-07 江苏先声药业有限公司 Estrogen receptor modulators and uses thereof
WO2022001971A1 (en) * 2020-06-28 2022-01-06 南京明德新药研发有限公司 Indazole-fused cyclic compound
AU2021366217A1 (en) 2020-10-19 2023-06-22 Sanofi Substituted 6,7-dihydro-5h-benzo[7]annulene compounds and their derivatives, processes for their preparation and therapeutic uses thereof
WO2022084298A1 (en) 2020-10-19 2022-04-28 Sanofi Substituted 6,7-dihydro-5h-benzo[7]annulene compounds and their derivatives, processes for their preparation and therapeutic uses thereof
JP2023551192A (en) 2020-11-23 2023-12-07 サノフイ Panel of ER-regulated genes for use in monitoring endocrine therapy in breast cancer
KR20230112626A (en) * 2020-11-23 2023-07-27 사노피 Combinations comprising abemaciclib and 6-(2,4-dichlorophenyl)-5-[4-[(3S)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7H-benzo[7]annulene-2-carboxylic acid
CN116867778A (en) * 2021-02-04 2023-10-10 正大天晴药业集团股份有限公司 Benzo seven-membered ring type difunctional compound and application thereof
TW202304425A (en) 2021-04-12 2023-02-01 法商賽諾菲公司 Combination comprising ribociclib and amcenestrant
TW202304424A (en) 2021-04-12 2023-02-01 法商賽諾菲公司 Combination comprising everolimus and amcenestrant
TW202313558A (en) * 2021-07-08 2023-04-01 大陸商勤浩醫藥(蘇州)有限公司 Benzo-seven-membered heterocyclic compound and application thereof
WO2023287938A1 (en) 2021-07-15 2023-01-19 Teva Pharmaceuticals International Gmbh Solid state forms of amcenestrant
WO2023125700A1 (en) * 2021-12-28 2023-07-06 南京明德新药研发有限公司 Salt form and crystal form of tetrahydrocyclohepta indazole compound
TW202400136A (en) 2022-03-13 2024-01-01 法商賽諾菲公司 Treatment of breast cancer with amcenestrant
WO2023187086A1 (en) 2022-03-31 2023-10-05 Sanofi Amorphous solid form of amcenestrant
WO2023198879A1 (en) 2022-04-15 2023-10-19 Sanofi Novel substituted fluorinated n-propyl-pyrrolidine compounds, processes for their preparation and therapeutic uses thereof
WO2023198901A1 (en) 2022-04-15 2023-10-19 Sanofi Novel substituted 4-amino-4-oxo-but-2-enyl derivatives, processes for their preparation and therapeutic uses thereof
WO2023198905A1 (en) 2022-04-15 2023-10-19 Sanofi Novel substituted fluorinated vinyl-n-propyl-pyrrolidine compounds, processes for their preparation and therapeutic uses thereof
WO2023198904A1 (en) 2022-04-15 2023-10-19 Sanofi Substituted 6,7-dihydro-5h-benzo[7]annulene derivatives, processes for their preparation and therapeutic uses thereof
WO2023198903A1 (en) 2022-04-15 2023-10-19 Sanofi Novel substituted fluorinated n-propyl-pyrrolidine and n‑propyl-azetidine compounds, processes for their preparation and therapeutic uses thereof
WO2023198907A1 (en) 2022-04-15 2023-10-19 Sanofi Substituted 6,7-dihydro-5h-benzo[7]annulene derivatives, processes for their preparation and therapeutic uses thereof
WO2024006776A1 (en) * 2022-06-27 2024-01-04 Relay Therapeutics, Inc. Estrogen receptor alpha degraders and medical use thereof
WO2024042152A1 (en) 2022-08-25 2024-02-29 Sanofi Novel substituted 2-carbonyl-benzothiophene-6- carboxylic acid derivatives, processes for their preparation and therapeutic uses thereof
WO2024042185A1 (en) 2022-08-25 2024-02-29 Sanofi Novel substituted tetrahydroisoquinoline-6- carboxylic acid derivatives, processes for their preparation and therapeutic uses thereof.
WO2024042157A1 (en) 2022-08-25 2024-02-29 Sanofi Novel substituted quinoline and tetrahydronaphthalene carboxylic acid derivatives and therapeutic uses thereof
WO2024042187A1 (en) 2022-08-25 2024-02-29 Sanofi Novel substituted benzothiophene-6-carboxylic acid derivatives, processes for their preparation and therapeutic uses thereof
WO2024042163A1 (en) 2022-08-25 2024-02-29 Sanofi Novel substituted 2,3,4,9-tetrahydro-1h-pyrido[3,4-b]indole carboxylic acid derivatives, processes for their preparation and therapeutic uses thereof
WO2024052518A1 (en) 2022-09-09 2024-03-14 Sanofi Substituted tetrahydrocyclohepta[e]indole derivatives, processes for their preparation and therapeutic uses thereof
WO2024100236A1 (en) 2022-11-11 2024-05-16 Astrazeneca Ab Combination therapies for the treatment of cancer

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1752792A (en) * 1991-03-08 1992-10-06 Rhone-Poulenc Rorer International (Holdings) Inc. Multicyclic tertiary amine polyaromatic squalene synthetase inhibitors
DE19833786A1 (en) * 1998-07-18 2000-01-20 Schering Ag New diphenyl-benzocycloheptene derivatives, are tissue-selective estrogens and antiestrogens useful e.g. for treating osteoporosis or hormone-dependent tumors or in hormone replacement therapy
ATE286893T1 (en) 2001-01-24 2005-01-15 Chiesi Farma Spa 2H-1-BENZOPYRAN DERIVATIVES, PROCESSES FOR THEIR PRODUCTION AND PHARMACEUTICAL COMPOSITIONS
JP2005528320A (en) 2001-08-11 2005-09-22 ブリストル−マイヤーズ・スクイブ・ファーマ・カンパニー Selective estrogen receptor modulator
JP4554219B2 (en) 2002-04-24 2010-09-29 メルク・シャープ・エンド・ドーム・コーポレイション Estrogen receptor modulator
JP4500689B2 (en) 2002-12-26 2010-07-14 エーザイ・アール・アンド・ディー・マネジメント株式会社 Selective estrogen receptor modulator
JP4947406B2 (en) * 2003-08-29 2012-06-06 小野薬品工業株式会社 Compound having S1P receptor binding ability and pharmaceutical use thereof
MX2007000036A (en) 2004-06-25 2007-05-18 Johnson & Johnson Quaternary salt ccr2 antagonists.
US20050288238A1 (en) * 2004-06-28 2005-12-29 Pfizer Inc Benzocyclodecane derivatives with antitumor activity
DE102005014090A1 (en) * 2005-03-22 2006-09-28 Schering Ag 5H-Benzocycloheptender derivatives, process for their preparation and their use as anti-inflammatory agents
CA2611712C (en) 2005-06-14 2014-05-13 Baylor University Combretastatin analogs with tubulin binding activity
EP2048126A1 (en) 2007-10-11 2009-04-15 Bayer Schering Pharma AG Benzocycloheptane derivatives as selectively active oestrogens
EP2090579A1 (en) * 2008-01-29 2009-08-19 Sanofi-Aventis Substituted heteroarylamide diazepinopyrimidone derivatives
DE102010030538A1 (en) 2010-06-25 2011-12-29 Bayer Schering Pharma Aktiengesellschaft 6,7-Dihydro-5H-benzo [7] annulene derivatives, process for their preparation, pharmaceutical preparations containing them and their use for the preparation of medicaments
GB2483736B (en) 2010-09-16 2012-08-29 Aragon Pharmaceuticals Inc Estrogen receptor modulators and uses thereof
US20120130129A1 (en) * 2010-11-16 2012-05-24 Baylor University Efficient Method for Preparing Functionalized Benzosuberenes
TW201329025A (en) * 2011-11-01 2013-07-16 Astex Therapeutics Ltd Pharmaceutical compounds
DE102011087987A1 (en) 2011-12-08 2013-06-13 Bayer Intellectual Property Gmbh 6,7-Dihydro-5H-benzo [7] annulene derivatives, process for their preparation, pharmaceutical preparations containing them and their use for the preparation of medicaments
CN102584687A (en) 2011-12-30 2012-07-18 北京赛林泰医药技术有限公司 Ethylene derivatives used as selective estrogen receptor modulators
CA2861939A1 (en) * 2011-12-30 2013-07-04 Centaurus Biopharma Co., Ltd. Novel arylalkene derivatives and use thereof as selective estrogen receptor modulators
AU2014220838A1 (en) * 2013-02-19 2015-09-10 Bayer Pharma Aktiengesellschaft Bicyclo 2,3-benzodiazepines and spirocyclically substituted 2,3-benzodiazepines
WO2015028409A1 (en) * 2013-08-27 2015-03-05 Bayer Pharma Aktiengesellschaft 6,7-dihydro-5h-benzo[7]annulene derivatives, method for the preparation thereof, pharmaceutical preparations comprising them, and the use thereof for producing medicaments
US9980947B2 (en) 2014-12-18 2018-05-29 Genentech, Inc. Tetrahydro-pyrido[3,4-b]indole estrogen receptor modulators and uses thereof
JP6807841B2 (en) 2014-12-18 2021-01-06 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト Estrogen receptor modulator and its use
IL297369B1 (en) 2015-04-29 2024-02-01 Radius Pharmaceuticals Inc Rad1901 for use in a method of treatmenet of mutant estrogen receptor positive breast cancer or a mutanat estrogen receptor positive ovarian cancer
CN106924210A (en) 2015-12-29 2017-07-07 北京新领先医药科技发展有限公司 A kind of capsule containing Pabuk former times profit cloth and preparation method thereof
PL3416962T3 (en) 2016-02-15 2021-11-22 Sanofi 6,7-dihydro-5h-benzo[7]annulene derivatives as estrogen receptor modulators
SG11201903908PA (en) 2016-11-17 2019-05-30 Sanofi Sa Novel substituted n-(3-fluoropropyl)-pyrrolidine compounds, processes for their preparation and therapeutic uses thereof

Also Published As

Publication number Publication date
ECSP18069466A (en) 2018-09-30
IL277750B (en) 2022-06-01
MA44226B1 (en) 2021-07-29
CN108884079B (en) 2021-03-05
DK3524600T3 (en) 2022-02-07
JP6425852B1 (en) 2018-11-21
SG10202106024XA (en) 2021-07-29
HRP20211043T1 (en) 2021-10-01
US20200392081A1 (en) 2020-12-17
MX2020011469A (en) 2021-09-30
BR112018016490A2 (en) 2018-12-18
KR20180105759A (en) 2018-09-28
JP6868142B2 (en) 2021-05-12
CA3014424A1 (en) 2017-08-24
EP3524600A1 (en) 2019-08-14
TN2018000285A1 (en) 2020-01-16
TW201741285A (en) 2017-12-01
US20210323916A1 (en) 2021-10-21
HUE057892T2 (en) 2022-06-28
JP2020128385A (en) 2020-08-27
AR107616A1 (en) 2018-05-16
CY1125165T1 (en) 2023-06-09
EA201891841A1 (en) 2019-01-31
IL277750A (en) 2020-11-30
US11214541B2 (en) 2022-01-04
ES2881508T3 (en) 2021-11-29
JP6476343B2 (en) 2019-02-27
PT3416962T (en) 2021-07-23
DOP2018000184A (en) 2019-01-31
US20180079720A1 (en) 2018-03-22
LT3416962T (en) 2021-07-12
KR20220098057A (en) 2022-07-08
MX2018009908A (en) 2018-09-07
ES2906208T3 (en) 2022-04-13
IL261099B (en) 2020-10-29
AU2017221083A1 (en) 2018-10-04
EA034994B1 (en) 2020-04-15
CR20180442A (en) 2018-12-21
JP2018537406A (en) 2018-12-20
PL3416962T3 (en) 2021-11-22
JP2019031537A (en) 2019-02-28
PE20181893A1 (en) 2018-12-11
EP3416962A1 (en) 2018-12-26
TW202138348A (en) 2021-10-16
RS62132B1 (en) 2021-08-31
EA038639B1 (en) 2021-09-28
AU2021225215B2 (en) 2023-05-25
TWI737681B (en) 2021-09-01
AU2021225215A1 (en) 2021-09-30
MA46479A (en) 2019-08-14
US9714221B1 (en) 2017-07-25
CL2018002290A1 (en) 2018-10-05
WO2017140669A1 (en) 2017-08-24
ZA201805137B (en) 2023-09-27
US20220073460A1 (en) 2022-03-10
UY37124A (en) 2017-09-29
US20170233340A1 (en) 2017-08-17
US20240150284A1 (en) 2024-05-09
DK3416962T3 (en) 2021-07-26
JP2019081776A (en) 2019-05-30
EP3524600B1 (en) 2021-11-17
EA202090255A2 (en) 2020-05-31
EA202090255A3 (en) 2020-07-31
CN112979524A (en) 2021-06-18
MY196486A (en) 2023-04-17
AU2017221083B2 (en) 2021-06-24
US10570090B2 (en) 2020-02-25
PH12018501679A1 (en) 2019-06-10
EP3416962B1 (en) 2021-05-05
TW202138349A (en) 2021-10-16
CN108884079A (en) 2018-11-23
JP6695457B2 (en) 2020-05-20
CO2018009534A2 (en) 2018-09-20
TWI779620B (en) 2022-10-01
IL261099A (en) 2018-10-31
HUE055107T2 (en) 2021-10-28
TWI779621B (en) 2022-10-01
SI3416962T1 (en) 2021-08-31

Similar Documents

Publication Publication Date Title
SG11201806829TA (en) 6,7-dihydro-5h-benzo[7]annulene derivatives as estrogen receptor modulators
SG11201903908PA (en) Novel substituted n-(3-fluoropropyl)-pyrrolidine compounds, processes for their preparation and therapeutic uses thereof
SG11201808678QA (en) Macrocyclic inhibitors of the pd-1/pd-l1 and cd80/pd-l1 protein/protein interactions
SG11201806863WA (en) Tetracyclic pyridone compounds as antivirals
SG11201908947QA (en) Process for the preparation of 6-(cyclopropaneamido)-4-((2-methoxy-3-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)amino)-n-(methyl-d3)pyridazine-3-carboxamide
SG11201804170RA (en) Polycyclic tlr7/8 antagonists and use thereof in the treatment of immune disorders
SG11201803627XA (en) N-substituted indole derivatives as pge2 receptor modulators
SG11201811431VA (en) Multispecific antibodies against cd40 and cd137
SG11201808990QA (en) Compositions for topical application of compounds
SG11201807573VA (en) Methods for providing single-stranded rna
SG11201909011PA (en) Niraparib compositions
SG11201403402VA (en) Compounds
SG11201500005SA (en) Pyrimidine pyrazolyl derivatives
SG11201810485SA (en) Substituted carbonucleoside derivatives useful as anticancer agents
SG11201908326YA (en) Methods of treating neurodegenerative diseases
SG11201808106YA (en) Use of masitinib for treatment of an amyotrophic lateral sclerosis patient subpopulation
SG11201811230RA (en) Compositions and methods for reducing ocular neovascularization
SG11201809497RA (en) Processes for preparing phosphorodiamidate morpholino oligomers
SG11201406973PA (en) Complement pathway modulators and uses thereof
SG11201900904PA (en) Methods for cross coupling
SG11201907364WA (en) Anti-tryptase antibodies, compositions thereof, and uses thereof
SG11202000333UA (en) Bicyclic ketone compounds and methods of use thereof
SG11201909311TA (en) Triterpene saponin synthesis, intermediates and adjuvant combinations
SG11201908097YA (en) Pyrimidine derivatives as pge2 receptor modulators
SG11201908729UA (en) Phenyl derivatives as pge2 receptor modulators